TTR and cardiac amyloidosis: While cardiac amyloidosis is the primary Val122Ile outcome [39], our finding is consistent with previous reports supporting that Val122Ile may be related to peripheral neuropathy symptoms that are more often reported with respect to other TTR amyloidogenic mutations [42].